FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975313529> ?p ?o ?g. }

• W1975313529 endingPage "1058" @default.
• W1975313529 startingPage "1042" @default.
• W1975313529 abstract "This clinical practice guideline, based on a systematic review, evaluates second-line or subsequent therapy for patients with recurrent or progressive non-small cell lung cancer.Relevant randomized trials and meta-analyses were identified through a systematic search of the literature. External feedback was obtained from practitioners in Ontario, and the guideline was approved by the provincial Lung Cancer Disease Site Group.Twenty-four randomized trials met the eligibility criteria. Two phase III trials demonstrated a significant benefit in overall survival and quality of life (QOL) for single-agent docetaxel. A pooled analysis comparing docetaxel administered weekly versus three-weekly found similar survival between the schedules and a non-significant reduction in febrile neutropenia for the weekly regimen. One phase III trial found that single-agent pemetrexed provided similar survival and QOL, compared to docetaxel. Another phase III trial demonstrated that oral topotecan was non-inferior to docetaxel for one-year survival rate, although QOL significantly favored docetaxel over topotecan. Docetaxel-based and other combination chemotherapy regimens have not been shown to be superior to single-agent docetaxel. One phase III trial revealed a statistically significant survival and QOL benefit for erlotinib over placebo for patients who were not eligible for further chemotherapy. Modest tumor response rates and symptom control have been demonstrated for gefitinib; however, a statistically significant survival benefit has not been established for gefitinib over placebo.Second-line or subsequent therapy with single-agent docetaxel, pemetrexed, or erlotinib offers patients a significant survival and QOL advantage." @default.
• W1975313529 created "2016-06-24" @default.
• W1975313529 creator A5012396032 @default.
• W1975313529 creator A5031200997 @default.
• W1975313529 creator A5036880675 @default.
• W1975313529 creator A5057361837 @default.
• W1975313529 date "2006-11-01" @default.
• W1975313529 modified "2023-10-02" @default.
• W1975313529 title "Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline" @default.
• W1975313529 cites W1839238860 @default.
• W1975313529 cites W1874925441 @default.
• W1975313529 cites W1920828316 @default.
• W1975313529 cites W1964948224 @default.
• W1975313529 cites W1970476748 @default.
• W1975313529 cites W1993474261 @default.
• W1975313529 cites W2019737858 @default.
• W1975313529 cites W2031059868 @default.
• W1975313529 cites W2037154789 @default.
• W1975313529 cites W2053432470 @default.
• W1975313529 cites W2062361000 @default.
• W1975313529 cites W2089220265 @default.
• W1975313529 cites W2120718661 @default.
• W1975313529 cites W2127405377 @default.
• W1975313529 cites W2130652363 @default.
• W1975313529 cites W2134667653 @default.
• W1975313529 cites W2135836172 @default.
• W1975313529 cites W2138297714 @default.
• W1975313529 cites W2138370803 @default.
• W1975313529 cites W2142661339 @default.
• W1975313529 cites W2142809967 @default.
• W1975313529 cites W2146404049 @default.
• W1975313529 cites W2147075384 @default.
• W1975313529 cites W2148718427 @default.
• W1975313529 cites W2153477391 @default.
• W1975313529 cites W2154346936 @default.
• W1975313529 cites W2158187340 @default.
• W1975313529 cites W2160131381 @default.
• W1975313529 cites W2166399931 @default.
• W1975313529 cites W2168431047 @default.
• W1975313529 cites W2243893298 @default.
• W1975313529 cites W2253090337 @default.
• W1975313529 cites W2259828625 @default.
• W1975313529 cites W2588936898 @default.
• W1975313529 cites W2589168334 @default.
• W1975313529 cites W4235950397 @default.
• W1975313529 cites W4252780045 @default.
• W1975313529 doi "https://doi.org/10.1016/s1556-0864(15)31641-5" @default.
• W1975313529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17409993" @default.
• W1975313529 hasPublicationYear "2006" @default.
• W1975313529 type Work @default.
• W1975313529 sameAs 1975313529 @default.
• W1975313529 citedByCount "54" @default.
• W1975313529 countsByYear W19753135292012 @default.
• W1975313529 countsByYear W19753135292013 @default.
• W1975313529 countsByYear W19753135292014 @default.
• W1975313529 countsByYear W19753135292015 @default.
• W1975313529 countsByYear W19753135292016 @default.
• W1975313529 countsByYear W19753135292017 @default.
• W1975313529 countsByYear W19753135292018 @default.
• W1975313529 countsByYear W19753135292019 @default.
• W1975313529 countsByYear W19753135292021 @default.
• W1975313529 countsByYear W19753135292022 @default.
• W1975313529 crossrefType "journal-article" @default.
• W1975313529 hasAuthorship W1975313529A5012396032 @default.
• W1975313529 hasAuthorship W1975313529A5031200997 @default.
• W1975313529 hasAuthorship W1975313529A5036880675 @default.
• W1975313529 hasAuthorship W1975313529A5057361837 @default.
• W1975313529 hasBestOaLocation W19753135291 @default.
• W1975313529 hasConcept C121608353 @default.
• W1975313529 hasConcept C126322002 @default.
• W1975313529 hasConcept C142724271 @default.
• W1975313529 hasConcept C143998085 @default.
• W1975313529 hasConcept C2776256026 @default.
• W1975313529 hasConcept C2776694085 @default.
• W1975313529 hasConcept C2777063308 @default.
• W1975313529 hasConcept C2777240266 @default.
• W1975313529 hasConcept C2778087573 @default.
• W1975313529 hasConcept C2778239845 @default.
• W1975313529 hasConcept C2778850193 @default.
• W1975313529 hasConcept C2779438470 @default.
• W1975313529 hasConcept C2780182762 @default.
• W1975313529 hasConcept C2780350996 @default.
• W1975313529 hasConcept C2780580887 @default.
• W1975313529 hasConcept C2780586478 @default.
• W1975313529 hasConcept C2781190966 @default.
• W1975313529 hasConcept C2781209748 @default.
• W1975313529 hasConcept C2781413609 @default.
• W1975313529 hasConcept C71924100 @default.
• W1975313529 hasConceptScore W1975313529C121608353 @default.
• W1975313529 hasConceptScore W1975313529C126322002 @default.
• W1975313529 hasConceptScore W1975313529C142724271 @default.
• W1975313529 hasConceptScore W1975313529C143998085 @default.
• W1975313529 hasConceptScore W1975313529C2776256026 @default.
• W1975313529 hasConceptScore W1975313529C2776694085 @default.
• W1975313529 hasConceptScore W1975313529C2777063308 @default.
• W1975313529 hasConceptScore W1975313529C2777240266 @default.
• W1975313529 hasConceptScore W1975313529C2778087573 @default.
• W1975313529 hasConceptScore W1975313529C2778239845 @default.

• next